Logo Prima Biomed

Welcome to the Newsroom

22 December 2016

Prima BioMed Announces Data from IMP321 AIPAC Clinical Trial in Breast Cancer



SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the “Company”) today announced interim data from the AIPAC Phase IIb clinical trial for IMP321 in metastatic breast cancer (Active Immunotherapy PAClitaxel). The initial data confirms previous trial results showing IMP321 is safe and well tolerated.